Home » FDA Scolds PET Drugmaker for Poor Data Integrity
FDA Scolds PET Drugmaker for Poor Data Integrity
The FDA slapped positron emission tomography (PET) drug manufacturer Cardinal Health with a Form 483 for poor data integrity and investigations into quality problems.
Drug GMP Report
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct